35 Participants Needed

Cyclophosphamide + Veliparib for Advanced Breast Cancer

Recruiting at 4 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: National Cancer Institute (NCI)
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, you cannot participate if you are on other investigational drugs or have not recovered from side effects of previous treatments. It's best to discuss your specific medications with the trial team.

What data supports the effectiveness of the drug Cyclophosphamide + Veliparib for advanced breast cancer?

Cyclophosphamide, a component of the treatment, has shown promising results in combination with other drugs for advanced breast cancer, improving survival and quality of life. Additionally, new targeted agents like Veliparib have been introduced to enhance outcomes in similar settings.12345

Is Cyclophosphamide safe for use in humans?

Cyclophosphamide, also known as Cytoxan or Neosar, has been used in various cancer treatments and is generally considered safe, but it can cause side effects like low blood cell counts and nausea. In some studies, it has been associated with less heart-related side effects compared to other drugs.36789

How is the drug combination of Cyclophosphamide and Veliparib unique for advanced breast cancer?

The combination of Cyclophosphamide and Veliparib is unique because it includes Veliparib, a PARP inhibitor (a drug that blocks an enzyme involved in repairing DNA damage in cells), which may enhance the effectiveness of Cyclophosphamide, especially in patients with advanced breast cancer that is resistant to other treatments.35101112

What is the purpose of this trial?

This phase I trial studies the side effects and best dose of cyclophosphamide and veliparib when given together in treating patients with breast cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving cyclophosphamide together with veliparib may work better in treating breast cancer.

Research Team

Joseph A. Sparano, M.D. | Albert ...

Joseph Sparano, MD

Principal Investigator

Montefiore Medical Center - Moses Campus

Eligibility Criteria

This trial is for adults with advanced or metastatic HER2/neu negative breast cancer who've had prior chemotherapy. They must have a certain level of blood cells, no severe liver/kidney issues, and be able to take oral meds. Pregnant women, those unable to use contraception, or patients with recent seizures or bowel obstructions can't join.

Inclusion Criteria

My cancer is not HER2 positive, as tested on my primary or metastatic tumor.
Your platelet count is at least 100,000 per microliter.
I've had chemotherapy for my cancer, or I have a BRCA1 or BRCA2 mutation.
See 15 more

Exclusion Criteria

Patients may not be receiving any other investigational agents
I have previously been treated with PARP inhibitors like veliparib or olaparib.
I haven't had radiotherapy in the last 3 weeks or recovered from previous treatment side effects.
See 9 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive veliparib and cyclophosphamide orally once daily on days 1-21, with courses repeating every 21 days in the absence of disease progression or unacceptable toxicity

21 days per cycle, up to 24 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 6 years

Treatment Details

Interventions

  • Cyclophosphamide
  • Veliparib
Trial Overview The study tests the combination of Cyclophosphamide (a chemo drug) and Veliparib (which blocks enzymes helping tumor growth) in treating advanced breast cancer. It aims to find the safest doses and observe side effects when these drugs are given together.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Treatment (veliparib, cyclophosphamide)Experimental Treatment3 Interventions
Patients receive veliparib orally PO QD and cyclophosphamide PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Cyclophosphamide is already approved in United States, European Union, Canada, Japan for the following indications:

πŸ‡ΊπŸ‡Έ
Approved in United States as Cytoxan for:
  • Breast cancer
  • Ovarian cancer
  • Multiple myeloma
  • Leukemia
  • Lymphoma
  • Rheumatoid arthritis
πŸ‡ͺπŸ‡Ί
Approved in European Union as Endoxan for:
  • Breast cancer
  • Ovarian cancer
  • Multiple myeloma
  • Leukemia
  • Lymphoma
  • Rheumatoid arthritis
πŸ‡¨πŸ‡¦
Approved in Canada as Neosar for:
  • Breast cancer
  • Ovarian cancer
  • Multiple myeloma
  • Leukemia
  • Lymphoma
  • Rheumatoid arthritis
πŸ‡―πŸ‡΅
Approved in Japan as Endoxan for:
  • Breast cancer
  • Ovarian cancer
  • Multiple myeloma
  • Leukemia
  • Lymphoma

Find a Clinic Near You

Who Is Running the Clinical Trial?

National Cancer Institute (NCI)

Lead Sponsor

Trials
14,080
Recruited
41,180,000+

Findings from Research

In a phase II study involving 44 patients with metastatic breast cancer, the combination of capecitabine and paclitaxel (XP) showed an overall response rate of 46.5%, indicating significant antitumor activity.
The treatment was well-tolerated, with manageable side effects, and resulted in a progression-free survival of 8.3 months and overall survival of 22.9 months, making it a viable option for patients with limited prior chemotherapy.
Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609.Taguchi, T., Yamamoto, D., Masuda, N., et al.[2015]
Epirubicin, which has lower cardiotoxicity than doxorubicin, allows for higher cumulative doses and is effective in treating metastatic breast cancer, making it a safer option for patients.
A phase III trial is set to compare the effectiveness of a concurrent epirubicin/taxane regimen against a sequential epirubicin/cyclophosphamide followed by taxane treatment in patients with operable node-positive breast cancer.
Rationale and design of a phase III trial of adjuvant sequential epirubicin/ cyclophosphamide and taxane versus concurrent epirubicin/taxane in operable node-positive breast cancer.Perez, EA.[2019]
In a study involving 66 patients with androgen-independent prostate carcinoma, the combination of weekly paclitaxel and estramustine phosphate led to a 42% rate of prostate-specific antigen (PSA) decline, indicating significant efficacy in managing the disease.
The treatment was generally well tolerated, with low rates of severe toxicities; however, there was one treatment-related death, highlighting the need for careful monitoring during therapy.
Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma.Vaughn, DJ., Brown, AW., Harker, WG., et al.[2015]

References

Chemotherapeutic Strategies for advanced breast cancer. [2007]
Sequential dose-dense adjuvant therapy with doxorubicin, paclitaxel, and cyclophosphamide. [2015]
Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609. [2015]
[Current status in the treatment of breast cancer. II. Adjuvant chemotherapy, palliative polychemotherapy, chemoimmunotherapy--rating and results (author's transl)]. [2019]
High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer. [2019]
Rationale and design of a phase III trial of adjuvant sequential epirubicin/ cyclophosphamide and taxane versus concurrent epirubicin/taxane in operable node-positive breast cancer. [2019]
Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma. [2015]
Adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes: vinorelbine plus epirubicin; vinorelbine plus epirubicin sequential followed up by paclitaxel; epirubicin plus cyclophosphamide; epirubicin plus cyclophosphamide sequential followed up by paclitaxel. A phase II study. [2019]
Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer. [2018]
VP16-213 and cyclophosphamide in advanced breast cancer. A phase II study. [2019]
Etoposide (VP-16-213) and cis-dichlorodiammineplatinum (DDP) in advanced breast carcinoma resistant to previous chemotherapy. [2015]
12.United Statespubmed.ncbi.nlm.nih.gov
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceΒ·Privacy PolicyΒ·CookiesΒ·Security